Appraisal of the pediatric crohn's disease activity index on four prospectively collected datasets: Recommended cutoff values and clinimetric properties

American Journal of Gastroenterology

Volumn 105, Issue 9, 2010, Pages 2085-2092

  Turner, Dan ^a   Griffiths, Anne M ^b   Walters, Thomas D ^b   Seah, Tong ^b   Markowitz, James ^c   Pfefferkorn, Marian ^d   Keljo, David ^e   Otley, Anthony ^f   Leleiko, Neal S ^g   MacK, David ^h   Hyams, Jeffrey ⁱ   Levine, Arie ^j  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c North Shore Long Island Jewish Health System ^*  (United States)

^d RILEY HOSPITAL FOR CHILDREN   (United States)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^f IWK HEALTH CENTRE   (Canada)

^g HASBRO CHILDREN'S HOSPITAL   (United States)

^h CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

ⁱ Farmington   (United States)

^j TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE;

ACCURACY; ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENTERITIS; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PEDIATRIC CROHN DISEASE ACTIVITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; REGISTER; RELIABILITY; REMISSION; SCORING SYSTEM; STEROID THERAPY; TREATMENT OUTCOME; AREA UNDER THE CURVE; PATHOPHYSIOLOGY; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; AREA UNDER CURVE; CHILD; CROHN DISEASE; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; REGISTRIES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77956344492     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.143     Document Type: Article

References (26)

1. Noble A, Turner D. Clinical outcomes in pediatric IBD. In: Mamula P, Baldassano R, Markowitz J (eds). Pediatric Inflammatory Bowel Disease, 1 st edn. Springer: NY, USA, p. 744, 2008
2. Best WR, Becktel JM, Singleton JW et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444
3. Turner D, Otley AR, Mack D et al. Development and evaluation of a Pediatric Ulcerative Colitis Activity Index (PUCAI): a prospective multicenter study. Gastroenterology 2007; 133: 423-432
4. Hyams JS, Ferry GD, Mandel FS et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12: 439-447
5. Griffiths AM, Otley AR, Hyams J et al. A review of activity indices and end points for clinical trials in children with Crohn's disease. Inflamm Bowel Dis 2005; 11: 185-196
6. Otley A, Loonen H, Parekh N et al. Assessing activity of pediatric Crohn's disease: which index to use? Gastroenterology 1999; 116: 527-531
7. Kundhal PS, Critch JN, Zachos M et al. Pediatric Crohn Disease Activity Index: responsive to short-term change. J Pediatr Gastroenterol Nutr 2003; 36: 83-89
8. Hyams J, Markowitz J, Otley A et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005; 41: 416-421
9. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73; quiz 1165-1166
10. Levine A, Kori M, Dinari G et al. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial. Inflamm Bowel Dis 2009; 15: 1055-1061
11. Turner D, Griffiths AM, Mack D et al. assessing disease activity in ulcerative colitis: patients or their physicians? Inflamm Bowel Dis 2010; 16: 651-656
12. Shrout P, Fleiss J. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979; 86: 420-428
13. Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis 1986; 39: 897-906
14. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40: 171-178
15. Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics 2000; 18: 419-423
16. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol 2002; 14: 109-114
17. Lassere MN, van der Heijde D, Johnson KR. Foundations of the minimal clinically important difference for imaging. J Rheumatol 2001; 28: 890-891
18. Lassere MN, van der Heijde D, Johnson K et al. Robustness and generalizability of smallest detectable difference in radiological progression. J Rheumatol 2001; 28: 911-913
19. Beaton DE. Understanding the relevance of measured change through studies of responsiveness. Spine 2000; 25: 3192-3199
20. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12-19
21. Turner D, Sch ü nemann HJ, Griffith LE et al. The minimal detectable change cannot reliably replace the minimal important difference. J Clin Epidemiol 2010; 63: 28-36
22. Liang MH. Evaluating measurement responsiveness. J Rheumatol 1995; 22: 1191-1192
23. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56: 395-407
24. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999; 52: 861-873
25. Wyrwich KW, Wolinsky FD. Identifying meaningful intra-individual change standards for health-related quality of life measures. J Eval Clin Pract 2000; 6: 39-49
26. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A): 5-36.